Results 111 to 120 of about 104,869 (316)

Chronic Prurigo of Nodular Type: A Review

open access: yesActa Dermato-Venereologica, 2017
Prurigo nodularis (PN) is a subtype of chronic prurigo presenting single to multiple symmetrically distributed, hyperkeratotic and intensively itching papules and nodules.
Claudia Zeidler   +5 more
doaj   +1 more source

Profitable War!

open access: yes, 2023
Profitable War!
Pruritus Migrans
core   +1 more source

PIEZO1 channels in cutaneous free nerve endings: novel insights into itch-scratch-mechanisms

open access: yesSignal Transduction and Targeted Therapy, 2023
Manuel Pedro Pereira   +2 more
doaj   +1 more source

Asocial Media

open access: yes, 2023
Asocial Media * QRt by PRURITUS MIGRANS * CC: BY-NC ...
Pruritus Migrans
core   +1 more source

Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study

open access: yesActa Dermato-Venereologica
The occurrence of pruritus in psoriasis was previously underestimated but is a significant burden. Secukinumab (SEC), a monoclonal anti-interleukin-17A antibody, efficiently controls signs of psoriasis, but the effect on pruritus and cutaneous ...
Lina Renkhold   +13 more
doaj   +1 more source

Bye-bye, Sailor!

open access: yes, 2022
Bye-bye, Sailor!
Pruritus Migrans
core   +1 more source

Effect of Sertraline on Uremic Pruritus Improvement in ESRD Patients

open access: yesInternational Journal of Nephrology, 2012
Background. Although uremic pruritus is a common and upsetting problem of chronic kidney disease, there is no approved treatment for it. This study was undertaken to find the efficiency of sertraline as a possible treatment for uremic pruritus. Methods.
Mansor Shakiba   +4 more
doaj   +1 more source

IGNIS

open access: yes, 2021
IGNIS - by PRURITUS MIGRANS - CC: BY-NC ...
Pruritus Migrans
core   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

Sailor's Bar

open access: yes, 2022
Sailor's Bar * QRt by PRURITUS MIGRANS * CC: BY-NC ...
Pruritus Migrans
core   +1 more source

Home - About - Disclaimer - Privacy